The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...